4 Analysts Have This To Say About AtaiBeckley
Throughout the last three months, 4 analysts have evaluated AtaiBeckley (NASDAQ:ATAI), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for AtaiBeckley, revealing an average target of $16.5, a high estimate of $25.00, and a low estimate of $11.00. Witnessing a positive shift, the current average has risen by 13.79% from the previous average price target of $14.50.
Understanding Analyst Ratings: A Comprehensive Breakdown
The standing of AtaiBeckley among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Ami Fadia | Needham | Maintains | Buy | $14.00 | $14.00 |
| Patrick R. Trucchio | HC Wainwright & Co. | Raises | Buy | $25.00 | $15.00 |
| Eddie Hickman | Guggenheim | Announces | Buy | $11.00 | - |
| Justin Walsh | Jones Trading | Announces | Buy | $16.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtaiBeckley. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AtaiBeckley compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of AtaiBeckley's stock. This comparison reveals trends in analysts' expectations over time.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AtaiBeckley's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on AtaiBeckley analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Unveiling the Story Behind AtaiBeckley
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
AtaiBeckley: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining AtaiBeckley's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1772.5% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: AtaiBeckley's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -8154.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): AtaiBeckley's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -40.25%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): AtaiBeckley's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -28.47%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.02.
Understanding the Relevance of Analyst Ratings
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.